Summary
Neuroendocrine tumours (NETs) are rare tumours with their clinical behaviour depending on the location of the primary and grade of differentiation. Recently, a number of randomised studies have been published focussing on pancreatic NETs which have demonstrated the efficacy of new therapeutic approaches including thyrosin-kinase inhibition and targetting the mTOR pathway. The objective of this review is to briefly sum up systemic treatment options in well differentiated pancreatic neuroendocrine tumours which are currently available.
Article PDF
Similar content being viewed by others
References
Modlin IM, Oberg K, Chung DC, et al. A Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 9(1): 61–72, 2008
Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch, 451(Suppl. 1): S9–27, 2007. Epub 2007 Aug 8
Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND. (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13
Yao JC, Hassan M, Phan A, et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 26: 3063–72, 2008
Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi MRole of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology, 93(4): 223–9, 2011
Thompson GB, Van Heerden JA, Grant CS, et al. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery, 104: 1011–7, 1988
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET), clinicalTrials.gov Identifier: NCT00353496
Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet- cell carcinoma. N Engl J Med, 326: 519–23, 1992
Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 22: 4762–71, 2004
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 117(2): 268–75, 2011. doi: 10.1002/cncr.25425
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 364(6): 501–13, 2011
Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 364(6): 514–23, 2011
Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol, 28(1): 69–76, 2010
Kulke MH, Anthony LB, Bushnell DL, et al. North American Neuroendocrine Tumor Society (NANETS) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas, 39(6): 735–52, 2010
Falconi M, Bartsch DK, Eriksson B, et al. O'Toole D ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System. Well-Differentiated Pancreatic Non-Functioning Tumors Neuroendocrinology, 2011
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Troch, M., Kiesewetter, B. & Raderer, M. Pancreatic neuroendocrine tumours – new therapeutic concepts. memo 5, 63–65 (2012). https://doi.org/10.1007/s12254-012-0339-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-012-0339-y